 4. Follicular lymphoma, grade 3 follicular large cell lymphoma: If eligible for a current large cell lymphoma protocol, that alternative protocol is recommended, particularly grade 3b or FLCL patients characterized as large non-cleaved cell. However, both FND and rituximab have established efficacy in FLCL, so if a patient is not eligible for a protocol for aggressive lymphoma e.g., because of SCCL in the marrow, then registration on this trial is permitted. 